Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753721 | 0.80 | PTPRC (0.41) | PTPRCMAPTNPSR1KMT2APAX8 | |
| SCHEMBL14445422 | 0.79 | PTPRC (0.41) | PTPRCMAPTNPSR1KMT2APAX8 | |
| SCHEMBL11537268 | 0.77 | PTPRC (0.39) | PTPRCMAPTNPSR1KMT2APAX8 | |
| SCHEMBL14445423 | 0.74 | RPS6KB2 (0.45) | PTPRCMAPTNPSR1KMT2APAX8 | |
| SCHEMBL25286295 | 0.73 | LMNA (0.45) | MAPTKMT2AGAAMAPK1ALDH1A1 | |
| SCHEMBL22775395 | 0.73 | GRM8 (0.53) | PTPRCGRM8GRM4GRM6 | |
| SCHEMBL9320506 | 0.72 | KCNH2 (0.47) | ALDH1A1 | |
| SCHEMBL2136898 | 0.71 | XDH (0.40) | PTPRCMAPTNPSR1KMT2A | |
| SCHEMBL2016370 | 0.70 | PTPRC (0.46) | PTPRCMAPTNPSR1KMT2APAX8 | |
| SCHEMBL259685 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102448952-B | Antiviral compounds and uses thereof | ABBVIE (US) | 2014-10-29 | — | — | CN | disclosed |
| US-8741914-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2421845-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LAB (US) | 2013-04-17 | — | — | EP | disclosed |
| CN-102448952-A | Antiviral compounds and uses thereof | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2421845-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Abbott Laboratories (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010111437-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7342116-B2 | Process for producing heterocyclic aldehyde | KOEI CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100104-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | PTPRC 576/4885MAPT 4152/4885NPSR1 4135/4885 |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | PTPRC 3076/4885MAPT 3576/4885NPSR1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.